Citations

Clear

813 citation(s) found for "He, Helen".

TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS
Cunningham, Kathleen M. , Maulding, Kirstin , Ruan, Kai , Şentürk, Mümine , Grima, Jonathan C., Sung, Hyun , Zuo, Zhongyuan , Song, Helen, Gao, Junli , Dubey, Sandeep Kumar , Zhang, Ke , Bellen, Hugo J , Lloyd, Thomas E , Rothstein, Jeffrey D. , Zhang, Ke , Bellen, Hugo J.

Mayo Clinic

eLife | December 10, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.59419 | PMID 33300868 Get It

Disrupted nucleocytoplasmic transport (NCT) has been implicated in neurodegenerative disease pathogenesis; however, the mechanisms by which disrupted NCT causes neurodegeneration remain unclear. In a Drosophila screen, we identified ref(2)P/p62 , a key regulator of autophagy, as a potent suppressor of neurodegeneration caused by the GGGGCC hexanucleotide repeat expansion (G4C2 HRE) in C9orf72 that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). We found that p62 is increased and forms ubiquitinated aggregates due to decreased autophagic cargo degradation. Immunofluorescence and electron microscopy of Drosophila tissues demonstrate an accumulation of lysosome-like organelles that precedes neurodegeneration. These phenotypes are partially caused by cytoplasmic mislocalization of Mitf/TFEB, a key transcriptional regulator of autophagolysosomal function. Additionally, TFEB is mislocalized and downregulated in human cells expressing GGGGCC repeats and in C9-ALS patient motor cortex. Our data suggest that the C9orf72 -HRE impairs Mitf/TFEB nuclear import, thereby disrupting autophagy and exacerbating proteostasis defects in C9-ALS/FTD.
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
Kane, John M. , Connelly, Mary, Ganjoo, Kristen N. , Heslin, Martin J. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Meyer, Christian F. , Pappo, Alberto S. , Paz, I. Benjamin , Petersen, Ivy A. , Poppe, Matthew M. , Riedel, Richard F. , Schuetze, Scott M. , Shabason, Jacob E. , Bergman, Mary Anne, George, Giby V. , Riedel, Richard F , Mehren, Margaret von , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , George, Suzanne , González, Ricardo , Liebner, David A. , Parkes, Amanda , Rubin, Brian P. , Sicklick, Jason Keith , Spraker, Matthew B. , Zimel, Melissa N.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1604-1612

10.6004/jnccn.2020.0058 | PMID 33285515 Get It

The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including the development of a separate and distinct guideline for gastrointestinal stromal tumors (GISTs); reconception of the management of desmoid tumors; inclusion of further recommendations for the diagnosis and management of extremity/body wall, head/neck sarcomas, and retroperitoneal sarcomas; modification and addition of systemic therapy regimens for sarcoma subtypes; and revision of the principles of radiation therapy for soft tissue sarcomas.
IMMU-15. HEPARIN INHIBITS THE EXTRACELLULAR VESICLE-MEDIATED INDUCTION OF IMMUNOSUPPRESSIVE MONOCYTES IN GLIOBLASTOMA
Tritz, Zachariah P. , Li, Helen , Geiger, Philipp , Peterson, Timothy E., Himes, Benjamin , Fain, Cori E. , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii107-ii107

10.1093/neuonc/noaa215.445 Get It

Abstract Glioblastoma (GBM) is the most common and fatal primary brain tumor in adults. The development of novel therapies is critical, as little has changed regarding the standard of care in nearly two decades. Immunotherapy holds much promise, as treatments including chimeric antigen receptor (CAR) T cells and immune checkpoint blockade inhibitors have transformed the treatment of a number of cancers in recent years. However, GBM patients exhibit profound immunosuppression, limiting the efficacy of these therapies. Understanding the mechanisms of GBM-mediated immunosuppression is critical to overcoming this barrier. GBM-derived extracellular vesicles (EVs) have been shown to mediate the induction of immunosuppressive monocytes, which may point to a mechanism of immunosuppression. EVs make initial contact with target cells through interactions between heparan sulfate proteoglycans, and soluble heparin has been shown to inhibit these interactions in some models. We demonstrate that soluble heparin inhibits the binding of GBM-derived EVs to monocytes in a dose-dependent manner, and that heparin treatment reduces the induction of immunosuppressive monocytes upon in vitro conditioning of monocytes with GBM-derived EVs (p< 0.01). Further, we demonstrate that heparin treated EV-conditioned monocytes are functionally less immunosuppressive than untreated EV-conditioned monocytes as measured by T cell proliferation in co-culture studies (p< 0.05). Taken together, these findings underscore the import of tumor-derived EVs in immunosuppression in GBM, and demonstrate the feasibility of targeting EV-monocyte interactions in treating GBM-mediated immunosuppression.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Steensma, David P. , Fenaux, Pierre , Eygen, Koen Van , Raza, Azra , Germing, Ulrich, Font, Patricia , Díez‐Campelo, María , Thépot, Sylvain , Vellenga, Edo , Patnaik, Mrinal M. , Jang, Jun Ho , Varsos, Helen, Bussolari, Jacqueline , Rose, Esther , Sherman, Laurie, Sun, Libo , Wan, Ying , Dougherty, Souria, Huang, Fei , Feller, Faye, Rizo, Aleksandra, Platzbecker, Uwe , Van Eygen, Koen , Font, Patricia , Thepot, Sylvain , Patnaik, Mrinal , Platzbecker, Uwe , Steensma, David P , Diez-Campelo, Maria , Santini, Valeria , Germing, Ulrich

Mayo Clinic

Journal of Clinical Oncology | November 19, 2020 | Volume: 39 | Issue: 1 | Pages: 48-56

10.1200/jco.20.01895 | PMID 33108243 Get It

PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of telomerase enzymatic activity, targets cells with active telomerase. We report efficacy, safety, and biomarker data for patients with LR MDS who are RBC transfusion dependent and who were relapsed/refractory to ESAs. PATIENTS AND METHODS In this two-part phase II/III study (MDS3001), the primary end point was 8-week RBC transfusion independence (TI) rate, with key secondary end points of 24-week RBC TI rate, TI duration, and hematologic improvement-erythroid. RESULTS Data from the phase II part of the study are reported. Of 57 patients enrolled and treated (overall population), 38 were non-del(5q) and hypomethylating agent and lenalidomide naïve (subset population). The 8- and 24-week RBC TI rates in the overall population were 37% and 23%, respectively, with a median TI duration of 65 weeks. In the subset population, 8- and 24-week RBC TI rates were 42% and 29%, respectively, with a median TI duration of 86 weeks. Eight-week TI rate was observed across all subgroups evaluated. Cytogenetic and mutational data revealed a reduction of the malignant clones, suggesting disease modification activity. The most common adverse events were cytopenias, typically reversible within 4 weeks. CONCLUSION Imetelstat treatment results in a meaningful, durable TI rate across a broad range of heavily transfused patients with LR MDS who are ineligible for or relapsed/refractory to ESAs. Biomarker analyses indicated effects on the mutant malignant clone.
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target
Bao, Riyue , Surriga, Oliver, Olson, Daniel J. , Allred, Jacob B., Zha, Yuanyuan , Labadie, Brian , Bastos, Bruno R. , Butler, Marcus O. , Hogg, David , Musi, Elgilda , Ambrosini, Grazia , Luke, Jason J. , Strand, Carrie A, Butler, Marcus O , Luke, Jason J , Strand, Carrie , Carll, Timothy Clifford , Münster, Pamela N. , Schwartz, Gary K. , Olson, Daniel

Mayo Clinic

Melanoma Research | November 6, 2020 | Volume: 31 | Issue: 1 | Pages: 27-37

10.1097/cmr.0000000000000701 | PMID 33170593 Get It

Uveal melanoma is a rare form of melanoma with particularly poor outcomes in the metastatic setting. In contrast with cutaneous melanoma, uveal melanoma lacks BRAF mutations and demonstrates very low response rates to immune-checkpoint blockade. Our objectives were to study the transcriptomics of metastatic uveal melanoma with the intent of assessing gene pathways and potential molecular characteristics that might be nominated for further exploration as therapeutic targets. We initially analyzed transcriptional data from The Cancer Genome Atlas suggesting PI3K/mTOR and glycolysis as well as IL6 associating with poor survival. From tumor samples collected in a prospective phase II trial (A091201), we performed a transcriptional analysis of human metastatic uveal melanoma observing a novel role for epithelial-mesenchymal transition associating with survival. Specifically, we nominate and describe initial functional validation of neuropillin-1 from uveal melanoma cells as associated with poor survival and as a mediator of proliferation and migration for uveal melanoma in vitro. These results immediately nominate potential next steps in clinical research for patients with metastatic uveal melanoma.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Ansell, Stephen M. , Barnes, Jeffrey A. , Clemens, Mark W. , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Pro, Barbara, Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shustov, Andrei R., Sokol, Lubomir , Torka, Pallawi , Torres‐Cabala, Carlos A. , William, Basem M. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, William, Basem , Torres-Cabala, Carlos , Hoppe, Richard T , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Goyal, Gaurav , Halwani, Ahmad , Kim, Youn H , Sokol, Lubomir , Wilcox, Ryan A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 5, 2020 | Volume: 18 | Issue: 11 | Pages: 1460-1467

10.6004/jnccn.2020.0053 | PMID 33152703 Get It

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.
Photodynamic Therapy in Refractory Mycosis Fungoides: A Prospective, Open-Label Study
Brumfiel, Caitlin M. , Severson, Kevin J. , Patel, Meera H. , Cumsky, Helen J.L., Ginos, Brenda, Janeczek, Monica, Rule, William G., DiCaudo, David J. , Pittelkow, Mark R. , Mangold, Aaron R. , Mangold, A R , Kosiorek, Heidi , Besch‐Stokes, Jake , Rosenthal, Allison

Mayo Clinic

Blood | November 4, 2020 | Volume: 136 | Issue: Supplement 1 | Pages: 32-32

10.1182/blood-2020-141119 Get It

Background:Case reports suggest photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is an effective treatment for refractory mycosis fungoides (MF). No prospective trials have examined the use of ALA-PDT in MF. Objective:We aimed to assess the efficacy of ALA-PDT in refractory MF. Methods:This was a prospective study at Mayo Clinic in Scottsdale, Arizona in patients ≥ 18 years with plaque-stage treatment-refractory MF. Monthly sessions of ALA with blue light PDT were administered for up to six months. Responses were measured by Composite Assessment of Index Lesion Severity (CAILS) and Physician Global Assessment (PGA). Ad hoc analysis with modified CAILS (mCAILS) was performed, eliminating hyperpigmentation from scoring. Results:Eleven patients (30 total lesions) were treated. Six patients completed the trial per protocol. Objective response rates were 36.4% by PGA (10.9-69.2%), 18.2% by CAILS (2.3-51.8%), and 36.4% by mCAILS (10.9-69.2%). Limitations:Five patients did not complete all six PDT cycles per protocol, possibly accounting for reduced efficacy. Conclusion:ALA-PDT with blue light irradiation was moderately effective and well tolerated in refractory plaque stage MF. Lower response rates compared to similar trials may be partially explained by utilization of strict lesional assessment criteria and other variations in methodology. Disclosures Mangold: MiRagen:Research Funding;Sun Pharma:Research Funding;Elorac:Research Funding;Kirin:Membership on an entity's Board of Directors or advisory committees;Solagenix:Research Funding. OffLabel Disclosure: Photodynamic therapy is a two-step therapy in which a drug that acts as a photosensitizer is administered to target a diseased tissue, followed by illumination with visible light to activate the drug and destroy the target tissue. PDT has been used to treat internal cancers as well as treatment of cancer and precancer of the skin.
Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease
Wong, Annette , Munt, Alexandra , Allman‐Farinelli, Margaret , Badve, Sunil V. , Boudville, Neil , Coolican, Helen, Chandra, Ashley N. , Coulshed, Susan, Fernando, Mangalee, Grantham, Jared J. , Haloob, Imad, Harris, David C.H. , Holt, Jane L., Johnson, David W. , Kumar, Karthik, Lee, Vincent , Lonergan, Maureen , Mai, Jun, Rangan, Anna , Roger, Simon D. , Saravanabavan, Sayanthooran , Sud, Kamal , Torres, Vicente E. , Vilayur, Eswari, Zhang, Jennifer Q. J. , Rangan, Gopala K. , Johnson, David W , Lee, Vincent W , Rangan, Anna , Sud, Kamal , Zhang, Jennifer Q J , Torres, Vicente E , Hawley, Carmel M.

Mayo Clinic

Nutrients | November 2, 2020 | Volume: 12 | Issue: 11 | Pages: 3376

10.3390/nu12113376 | PMID 33147804 Get It

The excess intake of dietary sodium is a key modifiable factor for reducing disease progression in autosomal dominant polycystic kidney disease (ADPKD). The aim of this study was to test the hypothesis that the scored salt questionnaire (SSQ; a frequency questionnaire of nine sodium-rich food types) is a valid instrument to identify high dietary salt intake in ADPKD. The performance of the SSQ was evaluated in adults with ADPKD with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 during the screening visit of the PREVENT-ADPKD trial. High dietary sodium intake (HSI) was defined by a mean 24-h urinary sodium excretion ≥ 100 mmol/day from two collections. The median 24-h urine sodium excretion was 132 mmol/day (IQR: 112–172 mmol/d) (n = 75; mean age: 44.6 ± 11.5 years old; 53% female), and HSI (86.7% of total) was associated with male gender and higher BMI and systolic blood pressure (p < 0.05). The SSQ score (73 ± 23; mean ± SD) was weakly correlated with log10 24-h urine sodium excretion (r = 0.29, p = 0.01). Receiving operating characteristic analysis showed that the optimal cut-off point in predicting HSI was an SSQ score of 74 (area under the curve 0.79; sensitivity 61.5%; specificity 90.0%; p < 0.01). The evaluation of the SSQ in participants with a BMI ≥ 25 (n = 46) improved the sensitivity (100%) and the specificity (100%). Consumers with an SSQ score ≥ 74 (n = 41) had higher relative percentage intake of processed meats/seafood and flavourings added to cooking (p < 0.05). In conclusion, the SSQ is a valid tool for identifying high dietary salt intake in ADPKD but its value proposition (over 24-h urinary sodium measurement) is that it may provide consumers and their healthcare providers with insight into the potential origin of sodium-rich food sources.
‘A sword of Damocles’: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study
Logeman, Charlotte , Sautenet, Bénédicte , Rangan, Gopala K. , Gutman, Talia , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Ahn, Curie , Coolican, Helen, Kao, Juliana Tze‐Wah , Gansevoort, Ron T., Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, C., Howell, Martin , Ju, Angela, Manera, Karine , Teixeira‐Pinto, Armando , Parasivam, Gayathri, Ahn, Curie , Torres, Vincent, Howell, Martin , Torres, Vicente E , Johnson, David W , Ong, Albert C M , Cho, Yeoungjee , Perrone, Ronald D. , Fowler, Kevin John , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Tong, Allison

Mayo Clinic

BMJ Open | October 10, 2020 | Volume: 10 | Issue: 10 | Pages: e038005

10.1136/bmjopen-2020-038005 | PMID 33040007 Get It

Background and objectives Presymptomatic testing is available for early diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD). However, the complex ethical and psychosocial implications can make decision-making challenging and require an understanding of patients’ values, goals and priorities. This study aims to describe patient and caregiver beliefs and expectations regarding presymptomatic testing for ADPKD. Design, setting and participants 154 participants (120 patients and 34 caregivers) aged 18 years and over from eight centres in Australia, France and Korea participated in 17 focus groups. Transcripts were analysed thematically. Results We identified five themes: avoiding financial disadvantage (insecurity in the inability to obtain life insurance, limited work opportunities, financial burden); futility in uncertainty (erratic and diverse manifestations of disease limiting utility, taking preventive actions in vain, daunted by perplexity of results, unaware of risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed by ambiguous information, medicalising family planning, family pressures); seizing control of well-being (gaining confidence in early detection, allowing preparation for the future, reassurance in family resilience); and anticipating impact on quality of life (reassured by lack of symptoms, judging value of life with ADPKD). Conclusions For patients with ADPKD, presymptomatic testing provides an opportunity to take ownership of their health through family planning and preventive measures. However, these decisions can be wrought with tensions and uncertainty about prognostic implications, and the psychosocial and financial burden of testing. Healthcare professionals should focus on genetic counselling, mental health and providing education to patients’ families to support informed decision-making. Policymakers should consider the cost burden and risk of discrimination when informing government policies. Finally, patients are recommended to focus on self-care from an early age.